Open AccessBerberine prevents stress-induced gut inflammation and visceral hypersensitivity and reduces intestinal motility in rats
Author(s) -
Zhichao Yu,
Yong-Xin Cen,
Ben-Hua Wu,
Cheng Wei,
Feng Xiong,
Defeng Li,
Tingting Liu,
MingHan Luo,
Liliangzi Guo,
Yingxue Li,
Lisheng Wang,
Jianyao Wang,
Jun Yao
Publication year - 2019
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v25.i29.3956
Subject(s) - medicine , inflammation , motility , irritable bowel syndrome , tumor necrosis factor alpha , inflammatory bowel disease , proinflammatory cytokine , immunology , pharmacology , biology , genetics , disease
Irritable bowel syndrome (IBS) is a common chronic non-organic disease of the digestive system. Berberine (BBR) has been used to treat patients with IBS, but the underlying therapeutic mechanism is little understood. We believe that BBR achieves its therapeutic effect on IBS by preventing stress intestinal inflammation and visceral hypersensitivity and reducing bowel motility.